Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistKin Meds was cited for misbranding compounded semaglutide and tirzepatide products sold through its website in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs when it was not, and made misleading claims suggesting the products were FDA-approved or equivalent to brand-name GLP-1 medications, when in fact compounded drugs lack FDA approval. These violations occurred in the company's website marketing and labeling of the compounded drug products offered for interstate commerce.